| First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (NCT05495295) | Phost'In Therapeutics | 2022-07-18 |
| Study of Tinostamustine for Adjuvant Treatment of Glioblastoma (NCT05432375) | Mundipharma Research Limited | 2022-07-01 |
| Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) (NCT05120284) | University of Florida | 2022-07-01 |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (NCT04978727) | Children's Oncology Group | 2022-07-01 |
| Multimodality MRI and Liquid Biopsy in GBM (NCT04776980) | Abramson Cancer Center at Penn Medicine | 2022-06-01 |
| AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients (NCT05182905) | Nader Sanai | 2022-05-27 |
| Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial (NCT04825275) | Milton S. Hershey Medical Center | 2022-05-13 |
| Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas (NCT04869449) | Milton S. Hershey Medical Center | 2022-05-11 |
| Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM (NCT05271240) | Northwell Health | 2022-04-27 |
| PreOperative Brain Irradiation in Glioblastoma (NCT03582514) | The Christie NHS Foundation Trust | 2022-04-19 |
| Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma (NCT05281731) | Washington University School of Medicine | 2022-04-18 |
| A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) (NCT05222802) | Katmai Pharmaceuticals Inc. | 2022-02-25 |
| Study of Pembrolizumab and M032 (NSC 733972) (NCT05084430) | University of Alabama at Birmingham | 2022-02-25 |
| Tamoxifen Versus Etoposide After First Recurrence in GBM Patients (NCT04765098) | AHS Cancer Control Alberta | 2022-01-28 |
| Chlorpromazine and Standard of Care in Glioblastoma (NCT05190315) | Mohammed Milhem | 2022-01-28 |
| Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma (NCT04977375) | Chirag G. Patil | 2021-12-09 |
| Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma (NCT05076513) | Nader Sanai | 2021-10-29 |
| IRD at Admission Predicts Survival of GBM Patients - a Prospective Pilot Study (NCT05402241) | University of Manitoba | 2021-10-21 |
| Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. (NCT04712721) | Novartis Pharmaceuticals | 2021-10-14 |
| Study of DSP-0390 in Patients With Recurrent High-Grade Glioma (NCT05023551) | Sumitomo Pharma America, Inc. | 2021-09-08 |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (NCT05218408) | Celularity Incorporated | 2021-09-01 |
| MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) (NCT04874506) | Matrix Biomed, Inc. | 2021-06-01 |
| UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: a Phase 2 Trial (NCT04726397) | Sunnybrook Health Sciences Centre | 2021-03-29 |
| Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection (NCT04608812) | OncoSynergy, Inc. | 2021-03-02 |
| BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels (NCT05375318) | Juan M Garcia-Gomez | 2021-03-01 |
| Surgical Nivolumab And Ipilimumab For Recurrent GBM (NCT04606316) | Patrick Wen, MD | 2021-02-01 |
| Study of Pamiparib in Newly Diagnosed and rGBM (NCT04614909) | Nader Sanai | 2021-01-11 |
| TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine (NCT04671459) | Prof. Franciszek Lukaszczyk Memorial Oncology Center | 2020-12-26 |
| Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (NCT04471844) | NovoCure Ltd. | 2020-12-08 |
| 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET) (NCT05608395) | Masaryk Memorial Cancer Institute | 2020-12-04 |
| Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma (NCT04530006) | CancerCare Manitoba | 2020-12-02 |
| Trial of AEO in New Glioblastoma (GBM) (NCT04450160) | MetVital, Inc. | 2020-12-01 |
| Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma (NCT04528680) | Northwestern University | 2020-10-29 |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM (NCT04489420) | Celularity Incorporated | 2020-10-01 |
| Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS (NCT04810182) | Istituto Oncologico Veneto IRCCS | 2020-09-10 |
| Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells (NCT03980249) | West Virginia University | 2020-09-01 |
| INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (NCT04295759) | Pediatric Brain Tumor Consortium | 2020-07-27 |
| Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients (NCT04446416) | NaviFUS Corporation | 2020-07-21 |
| Evaluation of GLR2007 for Advanced Solid Tumors (NCT04444427) | Gan and Lee Pharmaceuticals, USA | 2020-07-15 |
| Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM (NCT04492163) | NovoCure GmbH | 2020-07-14 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (NCT04478279) | Sapience Therapeutics | 2020-07-01 |
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma (NCT04421378) | Karyopharm Therapeutics Inc | 2020-06-08 |
| The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients (NCT05063682) | Chembrain LTD | 2020-05-15 |
| Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM (NCT04284306) | Assiut University | 2020-03-01 |
| Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM (NCT03961971) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-02-18 |
| Vacuolar ATPase and Drug Resistance of High Grade Gliomas (NCT05328089) | University of Milano Bicocca | 2020-01-30 |
| 18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme (NCT04588454) | Radboud University Medical Center | 2020-01-17 |
| Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) (NCT04222309) | Northwell Health | 2020-01-06 |
| Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM (NCT03705351) | Providence Health & Services | 2019-12-02 |
| LAM561 With RT and TMZ for Adults With Glioblastoma (NCT04250922) | Laminar Pharmaceuticals | 2019-12-01 |
| ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM) (NCT04277221) | Safe Save Medical Cell Sciences & Technology Co.,Ltd. | 2019-09-19 |
| HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors (NCT03911388) | M.D. Anderson Cancer Center | 2019-09-12 |
| A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients (NCT04116411) | Cecilia Soderberg-Naucler | 2019-09-04 |
| Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells (NCT03861598) | West Virginia University | 2019-07-19 |
| Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma (NCT03506139) | John M. Buatti | 2019-05-15 |
| 131I-IPA and Concurrent XRT in Recurrent GBM (NCT03849105) | Telix Pharmaceuticals (Innovations) Pty Limited | 2019-04-09 |
| The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients. (NCT03861299) | Jasper Gerritsen | 2019-04-01 |
| Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma (NCT03707457) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-03-22 |
| The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) (NCT03896958) | SpeciCare | 2019-03-21 |
| Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients (NCT03865355) | Novosibirsk State University | 2019-03-13 |
| A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT (NCT03866109) | Genenta Science | 2019-03-05 |
| A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection (NCT03834740) | St. Joseph's Hospital and Medical Center, Phoenix | 2019-01-19 |
| A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies (NCT03607643) | Leaf Vertical Inc. | 2019-01-15 |
| Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma (NCT03027388) | National Cancer Institute (NCI) | 2019-01-09 |
| Glycemic Impact on Glioblastoma Outcomes (NCT03235934) | University Health Network, Toronto | 2018-12-01 |
| MRI Predictors of Response to Tumor Treating Fields (NCT03642080) | New York Presbyterian Brooklyn Methodist Hospital | 2018-12-01 |
| Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma (NCT03665545) | University Hospital, Geneva | 2018-10-25 |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme (NCT03025893) | Amsterdam UMC, location VUmc | 2018-08-31 |
| ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy (NCT03712293) | InSightec | 2018-08-28 |
| Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients (NCT03626896) | NaviFUS Corporation | 2018-08-17 |
| A Trial of Ipatasertib in Combination With Atezolizumab (NCT03673787) | Institute of Cancer Research, United Kingdom | 2018-08-13 |
| Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma (NCT06562621) | Beijing Neurosurgical Institute | 2018-08-01 |
| UNITE Study: Understanding New Interventions With GBM ThErapy (NCT03419403) | AbbVie | 2018-07-30 |
| Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM (NCT03630289) | Northwell Health | 2018-07-27 |
| IA Carboplatin + Radiotherapy in Relapsing GBM (NCT03672721) | Université de Sherbrooke | 2018-07-10 |
| 3D Prediction of Patient-Specific Response (NCT03561207) | KIYATEC | 2018-06-11 |
| Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme (NCT03363659) | Wake Forest University Health Sciences | 2018-03-28 |
| Phase I Study of APX005M in Pediatric Central Nervous System Tumors (NCT03389802) | Pediatric Brain Tumor Consortium | 2018-03-01 |
| Phase I EGFR BATs in Newly Diagnosed Glioblastoma (NCT03344250) | University of Virginia | 2018-03-01 |
| Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM (NCT04195139) | University of Sydney | 2018-02-22 |
| Multi-site Validation and Application of a Consensus DSC-MRI Protocol (NCT03401866) | St. Joseph's Hospital and Medical Center, Phoenix | 2018-02-01 |
| Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression (NCT03050736) | Kintara Therapeutics, Inc. | 2017-12-17 |
| HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM (NCT03596086) | David Baskin MD | 2017-12-11 |
| Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects (NCT03382977) | VBI Vaccines Inc. | 2017-12-06 |
| BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma (NCT03119064) | Brown University | 2017-11-30 |
| Loupe-Based Intraoperative Fluorescence Imaging (NCT04780009) | Guoqiang Yu | 2017-11-17 |
| Nativis Voyager for Newly Diagnosed GBM (NCT03276286) | Nativis, Inc. | 2017-11-10 |
| VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM (NCT03149575) | DelMar Pharmaceuticals, Inc. | 2017-10-27 |
| 5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme (NCT03291990) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-10-18 |
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 (NCT03332355) | Vanquish Oncology, Inc. | 2017-10-01 |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (NCT03175224) | Apollomics Inc. | 2017-09-27 |
| Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma (NCT02704858) | Neonc Technologies, Inc. | 2017-08-01 |
| A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (NCT03152318) | Dana-Farber Cancer Institute | 2017-07-18 |
| Hypofractionated Radiation Therapy for Glioblastoma (NCT03212235) | Instituto do Cancer do Estado de São Paulo | 2017-06-05 |
| Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children (NCT02885324) | Indiana University | 2017-05-18 |
| TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM (NCT03780569) | NovoCure Ltd. | 2017-04-27 |
| Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma (NCT03072134) | Northwestern University | 2017-04-24 |
| Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma (NCT02858895) | Medicenna Therapeutics, Inc. | 2017-04-11 |
| Ketogenic Diets as an Adjuvant Therapy in Glioblastoma (NCT03075514) | University of Liverpool | 2017-04-01 |
| A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme (NCT02344355) | Bryan Allen | 2017-03-13 |